Enovis (ENOV) has opened 2026 with Q1 revenue of US$589.2 million and a basic EPS loss of US$0.15, while on a trailing 12 month basis the company recorded US$2.3 billion in revenue and a basic EPS loss of US$19.85. Over recent quarters, revenue has ranged between US$548.9 million and US$589.2 million, while quarterly basic EPS losses have moved between US$0.15 and US$12.06. This sets the scene for investors to focus on how efficiently that revenue base is converting into earnings. With analysts expecting a path to profitability over the coming years, the latest results put margins and the speed of any earnings improvement firmly in the spotlight for shareholders.

See our full analysis for Enovis.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the longer term stories investors follow about Enovis, and where those narratives might be tested by the latest figures.

Losses Narrow Compared With Recent Heavy Quarters

• Net income from continuing operations moved from losses of US$703.8 million in Q4 2024 and US$571.1 million in Q3 2025 to a loss of US$8.7 million in Q1 2026, while trailing 12 month losses sit at US$1.1 billion on US$2.3 billion of revenue.
• What stands out for the bearish view that focuses on widening losses over five years is how the recent quarterly loss compares with that longer stretch, as trailing 12 month net income of US$1.1 billion in losses and basic EPS of US$19.85 in losses line up against a much smaller Q1 2026 loss, which directly addresses concerns about ongoing deterioration.

Bears argue that a history of losses makes any setback look serious, yet Q1 2026 net income from continuing operations of US$8.7 million in losses against prior quarterly losses of US$518.9 million and US$571.1 million gives a very different scale to the recent period, and the trailing 12 month loss of US$1.1 billion sets the backdrop for judging how much progress still needs to be reflected in future reports.

Revenue Holds Around US$2.3b Scale

• On a trailing 12 month basis, revenue is US$2.3 billion, compared with US$2.1 billion at Q4 2024 and US$2.2 billion at Q1 2025, while the most recent quarterly revenue prints between US$548.9 million and US$589.2 million over the last six quarters.
• Supporters of the more bullish angle that highlights forecast earnings growth of 126.52% per year and an expected move to profitability within three years can point to this roughly US$2.3 billion revenue base as the platform for that shift, although the same data also shows revenue growth projected at 4.6% per year compared with a cited 11.4% for the broader US market, which means any profit story is tied more to margin improvement than to rapid top line expansion.

Consensus narrative notes that with Q1 2026 revenue of US$589.2 million and trailing 12 month revenue of US$2.3 billion, the company already operates at meaningful scale, so the key debate is whether analysts’ earnings forecasts on this base are realistic given that revenue growth of 4.6% per year is described as slower than the wider US market.

Valuation Signals Versus Profit Track Record

• The stock trades at US$27.25, which is well below the cited DCF fair value of US$55.48 and comes alongside a P/S of 0.7x compared with 2.8x for the US Medical Equipment industry and 6.9x for peers, while trailing 12 month basic EPS remains a loss of US$19.85.
• Supporters of a bullish stance often highlight the roughly 50.9% gap between the current price and DCF fair value and the lower P/S multiple, yet the same trailing 12 month data showing US$1.1 billion of net losses and a five year loss growth rate of 71.1% per year gives plenty of material for more cautious investors who focus on the company’s history of unprofitability.
• What is striking is that forecasts call for 126.52% annual earnings growth and a path to profitability within three years, while the trailing numbers still reflect sizeable losses over the last year.
• This mix of discounted valuation metrics against a loss making record makes it especially important for you to decide how much weight to place on the forecast turnaround versus the history in the provided figures.

If you want to see how others balance this valuation gap against the loss history, you can tap into a broader set of perspectives in one place via the Curious how numbers become stories that shape markets? Explore Community Narratives

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Enovis's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If the mixed signals on losses, revenue scale, and valuation feel unresolved, use the figures here to move quickly and test your own thesis, then weigh that view against the 3 key rewards

Explore Alternatives

Enovis currently combines sizeable trailing losses of US$1.1b and a history of unprofitability with forecasts that still need future reports to confirm any turnaround.

If that loss profile and uncertainty around profit timing make you cautious, consider shifting focus to companies that already prioritize resilience by screening for 72 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.